Roche parathyroid hormone osteoporosis research has Phase II candidate; NDA pending for Tasmar.
Executive Summary
ROCHE PARATHYROID HORMONE OSTEOPOROSIS RESEARCH HAS CANDIDATE IN PHASE II, the company indicated. A Roche-developed parathyroid hormone related peptide (RS-66271) was found in preclinical models to be more effective than parathyroid hormone in restoring bone mass density, Roche Bioscience Osteoporosis & Endocrine Research Director Brian Vickery, PhD, told a Cambridge Healthtech Institute meeting in Philadelphia Oct. 15 on osteoporosis therapies.